These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27867511)

  • 1. Is tapentadol different from classical opioids? A review of the evidence.
    Langford RM; Knaggs R; Farquhar-Smith P; Dickenson AH
    Br J Pain; 2016 Nov; 10(4):217-221. PubMed ID: 27867511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?
    Caraci F; Coluzzi F; Marinangeli F; Mercadante S; Rinonapoli G; Romualdi P; Nicora M; Dickenson AH
    Curr Med Res Opin; 2020 Jun; 36(6):1015-1024. PubMed ID: 32216591
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological rationale for tapentadol therapy: a review of new evidence.
    Romualdi P; Grilli M; Canonico PL; Collino M; Dickenson AH
    J Pain Res; 2019; 12():1513-1520. PubMed ID: 31190962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?
    Pergolizzi J; Alon E; Baron R; Bonezzi C; Dobrogowski J; Gálvez R; Jensen T; Kress HG; Marcus MA; Morlion B; Perrot S; Treede RD
    J Pain Res; 2011; 4():203-10. PubMed ID: 21887117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'.
    Raffa RB; Elling C; Tzschentke TM
    Adv Ther; 2018 Oct; 35(10):1471-1484. PubMed ID: 30206823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
    Gonçalves L; Friend LV; Dickenson AH
    Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
    Bagaphou TC; Cerotto V; Gori F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.